Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.

[1]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[2]  Edward A. Sausville,et al.  The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01* , 2000, The Journal of Biological Chemistry.

[3]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[4]  H. Piwnica-Worms,et al.  ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1 , 2001, Molecular and Cellular Biology.

[5]  David E. Williams,et al.  Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine* , 2001, The Journal of Biological Chemistry.

[6]  Laurence H. Hurley,et al.  DNA and its associated processes as targets for cancer therapy , 2002, Nature Reviews Cancer.

[7]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[8]  D. Boger,et al.  Mechanisms of in situ activation for DNA-targeting antitumor agents. , 2002, Chemical reviews.

[9]  S. Fesik,et al.  Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. , 2003, Molecular cancer therapeutics.

[10]  J. Bartek,et al.  Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing Radiation* , 2003, The Journal of Biological Chemistry.

[11]  D. Conrad,et al.  Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways , 2003, Cancer biology & therapy.

[12]  A. Gunasekera,et al.  Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents* , 2003, Journal of Biological Chemistry.

[13]  Y. Sánchez,et al.  Chk1 in the DNA damage response: conserved roles from yeasts to mammals. , 2004, DNA repair.

[14]  J. Wendoloski,et al.  Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. , 2004, Journal of medicinal chemistry.

[15]  Jiri Bartek,et al.  Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.

[16]  Dale L Boger,et al.  Sequence-selective DNA recognition: natural products and nature's lessons. , 2004, Chemistry & biology.

[17]  Baoguang Zhao,et al.  Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. , 2004, Molecular cancer therapeutics.

[18]  A. Sancar,et al.  Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. , 2004, Annual review of biochemistry.

[19]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[20]  Gaoquan Li,et al.  1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. , 2005, Journal of medicinal chemistry.

[21]  Andrew Potter,et al.  Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity. , 2005, Journal of medicinal chemistry.

[22]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[23]  P. Kovar,et al.  Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[24]  Lawrence C Kuo,et al.  3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. , 2006, Bioorganic & medicinal chemistry letters.

[25]  M. Prudhomme.  Novel checkpoint 1 inhibitors. , 2006, Recent patents on anti-cancer drug discovery.

[26]  Z. Tao,et al.  Chk1 inhibitors for novel cancer treatment. , 2006, Anti-cancer agents in medicinal chemistry.

[27]  Zhan Xiao,et al.  Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics , 2006, International journal of cancer.

[28]  Chang Park,et al.  Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[29]  Z. Ni,et al.  4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[30]  Chang Park,et al.  Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. , 2007, Journal of medicinal chemistry.

[31]  Chang Park,et al.  Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors. , 2007, Bioorganic & medicinal chemistry.